Alimera Sciences, Inc. (NASDAQ: ALIM) ("Alimera"), a pharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that the U.S. Food and Drug Administration (FDA) has approved ILUVIEN® for the treatment of diabetic macular edema (DME) in patients who have been previously treated with a course of corticosteroids and did not have a clinically significant rise in intraocular pressure (IOP). Alimera currently intends to begin selling ILUVIEN in the U.S. in the first quarter of 2015.
"We are very excited by this news late today and by the broader label ILUVIEN has been granted by the FDA," said Dan Myers, president and chief executive officer of Alimera. "We plan to issue a more detailed announcement on Monday morning."
Research links COVID-19 vaccines to temporary facial palsy in over 5,000 patients